Abstract
Acute kidney injury (AKI) is most commonly caused by sepsis and septic shock and it is associated with high mortality. Intravenous immunoglobulin (IVIG) therapy has been used for many years as replacement therapy in primary immunodeficiency disorders and has more recently been proposed to be beneficial in sepsis and septic shock. Many studies have been conducted in order to test this hypothesis. However, the results of clinical trials are conflicting and there is a high degree of heterogeneity among studies. We have reviewed the available literature, and we conclude that the current evidence to recommend IVIG therapy to reduce mortality in septic patients with AKI is limited.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Uchino S, Kellum JA, Bellomo R et al (2005) Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294(7):813–818
Werdan K (2001) Intravenous immunoglobulin for prophylaxis and therapy of sepsis. Curr Opin Crit Care 7(5):354–361
Keane WF, Hirata-Dulas CA, Bullock ML et al (1991) Adjunctive therapy with intravenous human immunoglobulin G improves survival of patients with acute renal failure. J Am Soc Nephrol 2(4):841–847
Landoni G, Bove T, Székely A et al (2013) Reducing mortality in acute kidney injury patients: systematic review and international web-based survey. J Cardiothorac Vasc Anesth 27(6):1384–1398
Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd (2013) Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 9, CD001090
INIS Collaborative Group, Brocklehurst P, Farrell B, King A et al (2011) Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 365(13):1201–1211
Pildal J, Gøtzsche PC (2004) Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 39(1):38–46
Laupland KB, Kirkpatrick AW, Delaney A (2007) Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 35(12):2686–2692
Kreymann KG, de Heer G, Nierhaus A, Kluge S (2007) Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 35(12):2677–2685
Turgeon AF, Hutton B, Fergusson DA et al (2007) Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 146(3):193–203
Almansa R, Tamayo E, Andaluz-Ojeda D et al (2015) The original sins of clinical trials with intravenous immunoglobulins in sepsis. Crit Care 19:90
Werdan K, Pilz G, Müller-Werdan U et al (2008) Immunoglobulin G treatment of postcardiac surgery patients with score-identified severe systemic inflammatory response syndrome-the ESSICS study. Crit Care Med 36(3):716–723
Burns ER, Lee V, Rubinstein A (1991) Treatment of septic thrombocytopenia with immune globulin. J Clin Immunol 11(6):363–368
Darenberg J, Ihendyane N, Sjölin J et al (2003) Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37(3):333–340
Hentrich M, Fehnle K, Ostermann H et al (2006) IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 34(5):1319–1325
Rodriguez A, Rello J, Neira J et al (2005) Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock 23(4):298–304
Schwab I, Nimmerjahn F (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13(3):176–189
Berger M (2013) Adverse effects of IgG therapy. J Allergy Clin Immunol Pract 1(6):558–566
Nydegger UE, Sturzenegger M (1999) Adverse effects of intravenous immunoglobulin therapy. Drug Saf 21(3):171–185
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Mathiasen, L., Maj, R., Paternoster, G. (2016). Can Intravenous Human Immunoglobulins Reduce Mortality in Patients with (Septic) Acute Kidney Injury?. In: Landoni, G., Pisano, A., Zangrillo, A., Bellomo, R. (eds) Reducing Mortality in Acute Kidney Injury. Springer, Cham. https://doi.org/10.1007/978-3-319-33429-5_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-33429-5_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-33427-1
Online ISBN: 978-3-319-33429-5
eBook Packages: MedicineMedicine (R0)